Education
About Us
Working with TipRanks
Follow Us
Phio Pharmaceuticals (PHIO)
NASDAQ:PHIO
PHIO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.97 - $9.79
Previous CloseN/A
Volume62.29K
Average Volume (3M)1.85M
Market Cap
$11.18M
Enterprise Value-$2.26M
Total Cash (Recent Filing)$13.28M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.41
Next Earnings
Aug 07, 2025EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding4,798,154
10 Day Avg. Volume5,224,353
30 Day Avg. Volume1,851,465
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.26K
Enterprise Value/Ebitda0.44
Forecast
1Y Price Target
$14.00Price Target Upside500.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPH-762 has already demonstrated impressive clinical activity and exhibited favorable safety in an early-stage Phase 1b trial.
Safety ProfilePH-762 administration was well-tolerated with no dose-limiting toxicities, serious adverse events, or clinically meaningful treatment-emergent adverse reactions reported.
Strategic PositioningPhio maintains business development optionality as it advances its portfolio of conditionally active siRNA therapies, positioning itself well for potential partnerships.
Bears Say
Clinical Trial RisksThe potential for the PH-762 Phase 1b study to generate data flow that could be positive catalysts through 2025 is underappreciated.
Funding ConcernsFactors that could impede reaching the price target include failed or inconclusive clinical trials and the inability to secure adequate funding.
Market CompetitionAlthough the skin cancer therapy market is becoming increasingly crowded, a high unmet need persists due to the tumor's high incidence, less than optimal efficacy of available treatment options, and drug resistance to systemic therapies.
Phio Pharmaceuticals News
PHIO FAQ
What was Phio Pharmaceuticals’s price range in the past 12 months?
Phio Pharmaceuticals lowest stock price was $0.96 and its highest was $9.79 in the past 12 months.
What is Phio Pharmaceuticals’s market cap?
Phio Pharmaceuticals’s market cap is $11.18M.
When is Phio Pharmaceuticals’s upcoming earnings report date?
Phio Pharmaceuticals’s upcoming earnings report date is Aug 07, 2025 which is in 2 days.
How were Phio Pharmaceuticals’s earnings last quarter?
Phio Pharmaceuticals released its earnings results on May 15, 2025. The company reported -$0.41 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.41.
Is Phio Pharmaceuticals overvalued?
According to Wall Street analysts Phio Pharmaceuticals’s price is currently Undervalued.
Does Phio Pharmaceuticals pay dividends?
Phio Pharmaceuticals does not currently pay dividends.
What is Phio Pharmaceuticals’s EPS estimate?
Phio Pharmaceuticals’s EPS estimate is -0.36.
How many shares outstanding does Phio Pharmaceuticals have?
Phio Pharmaceuticals has 4,798,154 shares outstanding.
What happened to Phio Pharmaceuticals’s price movement after its last earnings report?
Phio Pharmaceuticals reported an EPS of -$0.41 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.371%.
Which hedge fund is a major shareholder of Phio Pharmaceuticals?
Currently, no hedge funds are holding shares in PHIO
Company Description
Phio Pharmaceuticals
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
PHIO Stock 12 Month Forecast
Average Price Target
$14.00
▲(500.86%Upside)
Technical Analysis
Ibio
―
Evogene
―
Windtree Therapeutics
―
BioRestorative Therapies
―
Lixte Biotechnology Holdings
―
Ownership Overview
1.35% Insiders
1.21% Mutual Funds
<0.01% Other Institutional Investors
96.42% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---